Prenatal Testing for 22q11.2 Deletion Syndrome (22q) 

  Russ Jelsema, MD, Senior Medical Director at Natera, discusses the results of the SMART study, which evaluated the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 deletion syndrome (22q) in a cohort of...

Gene Silencing Therapy for Thalassemia in Development

  Giles Campion, MD, Head of R&D at Silence Therapeutics, discuss SLN124, a gene silencing therapy in development for the treatment of thalassemia. As Dr. Campion explains, thalassemia is an inherited blood disorder that reduces the production of functional...